Recent regulatory developments are reshaping how sponsors think about evidence, oversight, and operational readiness. In a New England Journal of Medicine Sounding Board, FDA leadership announced that one adequate and well-controlled clinical trial — supported by confirmatory evidence — could become the agency’s new default standard for approval.i The shift formally moves away from the long-stand…
Gaining regulatory approval for drugs targeting conditions that cannot ethically be studied in humans presents a unique challenge for drug developers. Without traditional clinical trial pathways, teams must rely on alternative methods to demonstrate efficacy and support approval. This webinar will explore how modeling and simulation are used to meet the requirements of the FDA […] The post Naviga…
In Brief Biotechnological advancements in medical devices can intensify risks and introduce new types of risk, despite their potential to greatly benefit health. Therapeutic products control […] The post How to overcome regulatory and ethical challenges regarding medical device? appeared first on Pubrica .
